SESN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 Mar 2023 @ 05:00):

Stats
今日成交量	1.78M
平均成交量	1.24M
市值	127.96M
EPS	$-53.13 ( 2023-09-29 )
Last Dividend	$0.360 ( 2023-03-06 )
Next Dividend	$0 ( N/A )
P/E	-6.29
ATR14	$0.0360 (5.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Kelly Steven	Buy	600 000	Stock Option (Right to Buy)
2023-06-06	Zweifach Sanford S	Buy	38 700	Stock Option (Right to Buy)
2023-06-06	Morris Richard Steven	Buy	238 000	Stock Option (Right to Buy)
2023-06-06	Torok Michael	Buy	38 700	Stock Option (Right to Buy)
2023-06-06	Klichinsky Michael	Buy	238 000	Stock Option (Right to Buy)

INSIDER POWER
76.64
Last 87 transactions
Buy: 18 644 112 \| Sell: 1 508 721

音量相关性

長: 0.00 (neutral)

短: -0.48 (neutral)

Signal:(57.604) Neutral

Sesen Bio Inc 相关性

10 最正相关
BOCH	0.945
SHSP	0.905
DYNT	0.846
SGC	0.836
MMAC	0.83
WWD	0.829
SYKE	0.826
LIVE	0.825
DGLY	0.823
ECOR	0.817

10 最负相关
GAINL	-0.898
APOP	-0.887
TDAC	-0.884
RMRM	-0.88
ISNS	-0.872
SVOK	-0.829
VERA	-0.822
AHPI	-0.801

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sesen Bio Inc 相关性 - 货币/商品

-0.56
( weak negative )

-0.49
( neutral )

0.00
( neutral )

-0.45
( neutral )

-0.31
( neutral )

0.47
( neutral )

Sesen Bio Inc 财务报表

Annual	2022
营收:	$40.00M
毛利润:	$40.00M (100.00 %)
EPS:	$-1.990

FY	2022
营收:	$40.00M
毛利润:	$40.00M (100.00 %)
EPS:	$-1.990

FY	2021
营收:	$26.54M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00184

FY	2020
营收:	$11.24M
毛利润:	$11.24 (0.00 %)
EPS:	$-0.190

Financial Reports:

No articles found.

Sesen Bio Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.360 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sesen Bio Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.13 - average (38.17%) | Divividend Growth Potential Score: 0.276 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.360	2023-03-06
Last Dividend	$0.360	2023-03-06
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.360	--
Avg. Dividend % Per Year	18.77%	--
Score	4.82	--
Div. Sustainability Score	5.13
Div.Growth Potential Score	0.276
Div. Directional Score	2.70	--

Next Divdend (Est)
(2024-04-29)

$0.720 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.82

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.360	56.30%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-1.605	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.761	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.910	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	7.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.27	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.42	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0257	-1.500	9.57	-10.00	[0 - 0.6]
interestCoverageTTM	11.34	1.000	6.91	6.91	[3 - 30]
operatingCashFlowPerShareTTM	0.0199	2.00	9.99	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0166	2.00	9.99	10.00	[0 - 20]
debtEquityRatioTTM	0.0593	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-1.510	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.292	1.000	9.49	9.49	[0.2 - 2]
assetTurnoverTTM	0.474	0.800	-0.172	-0.138	[0.5 - 2]
Total Score				5.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.312	1.000	-0.133	0	[1 - 100]
returnOnEquityTTM	-0.910	2.50	-7.21	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0166	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0199	2.00	9.99	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0158	1.000	-2.10	0	[0.1 - 0.5]
Total Score				0.276

Sesen Bio Inc

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.